Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

2013

Imaxio and VitamFero launch R&D partnership

2013

Imaxio and VitamFero announce the conclusion of an R&D partnership agreement. According to the terms of the agreement, the two firms will evaluate the combination of IMX313, Imaxio’s pro-immunogenic technology, and VitamFero’s live attenuated parasites, for vaccines development.

  • Lire la suite
  • Articles similaires

VitamFero expands its assets with excellent (...)

2013

VitamFero is a biotechnology firm in the Genopole cluster with a secondary facility in Tours (Indre & Loire, France) that develops novel veterinary and human vaccines against parasitic diseases. It announced filing of a new patent to cover the very good results obtained with its vaccine candidate against human ocular toxoplasmosis.

  • Lire la suite
  • Articles similaires

Genethon receives approval from the UK medicine (...)

2013

On January 10th 2013, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London.

  • Lire la suite
  • Articles similaires

VitamFero signs agreement with Merial to develop (...)

2013

VitamFero has announced a partnership agreement with Merial, the Animal Health Division of Sanofi Group, for developing new vaccines against significant production animal parasites.

  • Lire la suite
  • Articles similaires